Mirati Therapeutics, Inc. (MRTX)
-NasdaqCM 17.66 
2.51(16.57%) 4:00PM EDT
| Prev Close: | 15.15 |
|---|
| Open: | 15.00 |
|---|
| Bid: | 17.50 x 100 |
|---|
| Ask: | 18.00 x 1300 |
|---|
| 1y Target Est: | 26.41 |
|---|
| Beta: | 0.760 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 15.00 - 18.88 |
|---|
| 52wk Range: | 7.00 - 18.88 |
|---|
| Volume: | 73,611 |
|---|
| Avg Vol (3m): | 20,602 |
|---|
| Market Cap: | 175.84M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.86 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal ActivitiesEDGAR Online(Tue 4:10PM EDT)
- Wall Street Transcript Interview with Dr. Charles M. Baum, the President and CEO of Mirati Therapeutics, Inc. (MRTX)Wall Street Transcript(Fri, Sep 13)
- MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhEDGAR Online(Thu, Sep 5)
- Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of DirectorsMarketwired(Wed, Sep 4)
- Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of DirectorsMarketwired(Wed, Sep 4)
- MIRATI THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Aug 13)
- Mirati Therapeutics Reports Second Quarter 2013 Financial ResultsMarketwired(Mon, Aug 12)
- Mirati Therapeutics Reports Second Quarter 2013 Financial ResultsMarketwired(Mon, Aug 12)
- MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Mon, Aug 12)
- Mirati: Reborn After Reincorporation In The U.S. And Nasdaq Listingat Seeking Alpha(Mon, Aug 5)
- Mirati Therapeutics: Revamped And Ready To Go With A Targeted Oncology Pipelineat Seeking Alpha(Tue, Jul 23)
- MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or SEDGAR Online(Mon, Jul 22)
- Mirati Therapeutics to Voluntarily Delist from TSXMarketwired(Fri, Jul 19)
- Mirati Therapeutics to Voluntarily Delist from TSXMarketwired(Fri, Jul 19)
- LifeSci Advisors Initiates Coverage of Mirati TherapeuticsMarketwired(Thu, Jul 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.69 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.72 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of onco...
View More